Coronary artery bypass surgery is a definitive and
final approach to increase oxygen supply to the heart. Most cardiologists agree
that when all pharmaceutical modalities fail to increase oxygenation and reduce
workload of the heart, a surgical bypass is indicated. Statistics reveal 75-90%
of patients who are appropriate operative candidates and survive surgery have
reduction or disappearance of angina symptoms. Whether or not bypass surgery
prolongs life is controversial.
Chelation Therapy An Alternative to Bypass Surgery
(A Patient's Report by Dean Baxter, Director of Public Affairs • Arco
Corporation • Houston, Texas)
Relative mortality risk for bypass surgery is 4% for "good" surgical
candidates. Nearly 20% of operated patients develop a heart attack during the
The above statistics are under dispute. Some observers state mortality rates
for bypass surgery are 7.2-11.8%. A study at Mt. Sinai Hospital in New York
City indicates mortality rates at 4.5% for centers performing 200 or more surgeries
yearly, 9% for those centers performing 100 to 200 cases, and 12% in centers
performing less than 100 bypass surgeries. The risk of heart attack following
bypass surgery is between 5% and 40%. Reports demonstrate that 15-30% of vein
grafts (used in the bypass) become obstructed in one year.
There are research reports showing little or no beneficial improvement of heart
muscle functioning after bypass surgery.
Financially, bypass coronary surgery is good business. In 1976, 80,000 patients
underwent bypass surgery at an average cost of $32,000 for the surgery alone.
This totals $3 billion yearly. If this trend continues, there can be nearly
one-quarter million patients having the surgery in the upcoming years at an
expense of $100 billion. Thus surgery provides a busy cardiac surgeon the opportunity
to earn one to two million dollars each year.
With these medical and financial considerations in mind, we need alternative
approaches for severe coronary artery disease. One process, known as EDTA chelation
therapy, is an alternative to bypass surgery. The following report by Dean
Baxter, a retired oil executive of Arco, provides some insights into this chelation
Jonathan Collin, M.D.
Reprinted from the Port
Townsend Health Letter—Summer 1991
the Townsend Letter online.
Jonathan Collin | EDTA Chelation Therapy | Medical
Offices of Dr. Jonathan Collin | EDTA
Chelation Therapy links
Jonathan Collin, MD
All rights reserved